Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.
Actively Recruiting
Researchers are comparing two sedation methods for critically ill patients on mechanical ventilation inhaled isoflurane delivered via the Sedaconda ACD-S system versus intravenous propofol. This Phase IV, low-intervention, open-label, randomized controlled trial aims to evaluate which method leads to more ventilator-free days within 28 days post-randomization. The study focuses on patients expected to need deep sedation and mechanical ventilation for over 48 hours in the intensive care unit ICU. Participants will be randomly assigned to one of two groups. One group receives inhaled isoflurane starting at 3 mLh, adjusted to reach a target sedation level without exceeding 14 mLh, guided by end tidal isoflurane concentration. Short periods with higher concentrations may be used. The other group receives intravenous propofol starting at 0.5-1 mgkgh, carefully increased to reach the target sedation without exceeding 4 mgkgh. If sedation targets are not met, a secondary hypnotic may be added in either group. During the study, participants will be monitored for ventilator-free days at 28 days, ICU-free days, time to extubation, sedation effectiveness, use of additional sedatives, and delirium incidence and duration within 28 days. Researchers will also assess mental, cognitive, and quality of life outcomes at 90 days after hospital discharge. Safety, including treatment-related adverse events and mortality up to 60 days, will be tracked. The trial includes 620 patients across multiple centers, with data collected throughout the ICU stay and follow-up periods.